[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.171.146.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

August 2019 - April 2015

Decade

Year

Issue

March 2016, Vol 2, No. 3, Pages 287-404

Original Investigation

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):305-312. doi:10.1001/jamaoncol.2015.4921

This phase 2, open-label, single-arm study investigates the efficacy of first-line erlotinib therapy in patients with non–small-cell lung cancer with activating EGFR mutations and the use of erlotinib therapy after disease progression.

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):313-320. doi:10.1001/jamaoncol.2015.4482

This cohort study identifies 2237 patients with non–small-cell lung cancer and examines the association between young age at diagnosis and targetable genomic alterations and prognosis.

Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer

Abstract Full Text
free access has audio
JAMA Oncol. 2016;2(3):322-329. doi:10.1001/jamaoncol.2015.3856

This observational, population-based cohort study monitors time to chemotherapy postsurgery in subgroups of patients with breast cancer and hypothesizes that delaying initiation of adjuvant chemotherapy is associated with adverse outcomes.

Time to Surgery and Breast Cancer Survival in the United States

Abstract Full Text
open access
JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508

This study of 2 population-based databases of breast cancer from SEER-Medicare and the National Cancer Database compares time to surgery with overall and disease-specific survival.

Familial Risk in Patients With Carcinoma of Unknown Primary

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):340-346. doi:10.1001/jamaoncol.2015.4265

This nested case-control study of patients in the Utah Cancer Registry who received a diagnosis of cancer of unknown primary site between 1980 and 2010 quantifies the risk of cancer by site in first- and second-degree relatives and first cousins of these individuals.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

Abstract Full Text
open access
JAMA Oncol. 2016;2(3):348-357. doi:10.1001/jamaoncol.2015.4350

This study of patients allocated to the control arm of the STAMPEDE Trial explored the survival and the effect on survival of radiotherapy by nodal involvement in high-risk, hormone-naive men with newly diagnosed nonmetastatic prostate cancer starting long-term hormone therapy for the first time.

Quality of Life Analysis of a Radiation Dose–Escalation Study of Patients With Non–Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):359-367. doi:10.1001/jamaoncol.2015.3969

This study uses data from a trial comparing doses of radiation therapy for non–small-cell lung cancer to compare quality of life measures in patients given high vs low radiation doses.

Brief Report

Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):370-372. doi:10.1001/jamaoncol.2015.6053

This cohort study of 686 women with ovarian carcinoma to investigates whether PPMID mutations reflect an underlying cancer predisposition or consequence of cancer therapy.

Research Letter

Quality and Reporting Accuracy of Phase 1 Drug Radiation Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):390-391. doi:10.1001/jamaoncol.2015.4833

This Research Letter determines whether prospective therapeutic intent, follow-up time, and late toxic events are underreported in multimodality treatment phase 1 trials.

Chemotherapy-Related Chronic Myelogenous Leukemia: A Case Series of Patients With Germ Cell Tumor

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):391-392. doi:10.1001/jamaoncol.2015.4837

This Research Letter reports 3 cases of chromosome-positive chronic myelogenous leukemia (CML) following therapy for germ-cell tumors and poses questions regarding the connection of etoposide and cisplatin-containing combination chemotherapy and secondary CML.

Disease-Specific Hashtags for Online Communication About Cancer Care

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):392-394. doi:10.1001/jamaoncol.2015.3960

This study highlights the usefulness of agreement on disease-specific hashtags for effective online communication about cancer care.

Review

Multilocus Inherited Neoplasia Alleles Syndrome: A Case Series and Review

Abstract Full Text
open access
JAMA Oncol. 2016;2(3):373-379. doi:10.1001/jamaoncol.2015.4771

This case series and review presents examples of patients who harbor pathogenic mutations in multiple inherited cancer genes and describes previously published examples to illustrate the complex genotype-phenotype relationships in these cases.

JAMA Oncology Clinical Challenge

Bilateral Foot Gangrene

Abstract Full Text
JAMA Oncol. 2016;2(3):387-388. doi:10.1001/jamaoncol.2015.6156

A man in his 60s with hypertension, hyperlipidemia, and obesity presented with severe, constant bilateral lower extremity pain along with predominantly distal purplish discoloration of both feet. What is your diagnosis?

Viewpoint

Precision Medicine and Low- to Middle-Income Countries

Abstract Full Text
JAMA Oncol. 2016;2(3):293-294. doi:10.1001/jamaoncol.2015.5511

This Viewpoint discusses the importance of precision medicine for low- and middle-income countries, as well as ways it might be implemented.

Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?

Abstract Full Text
JAMA Oncol. 2016;2(3):295-296. doi:10.1001/jamaoncol.2015.5345

This Viewpoint discusses how the Drug Quality and Security Act has prohibited a beneficial practice of cancer drug reuse and proposes ways to solve this problem while still protecting consumers.

Oncology Pathways—Preventing a Good Idea From Going Bad

Abstract Full Text
JAMA Oncol. 2016;2(3):297-298. doi:10.1001/jamaoncol.2015.5778

This Viewpoint discusses the need for oncologist involvement in developing clinical pathways for cancer care.

From the JAMA Network

Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope?

Abstract Full Text
JAMA Oncol. 2016;2(3):380-381. doi:10.1001/jamaoncol.2015.4869

This commentary describes the findings of a study of long-term survival in patients with pancreatic cancer and calls for more research to help identify patients with the potential for long-term survival after pancreatic cancer resection.

Overtreatment of Low-Grade Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):382-383. doi:10.1001/jamaoncol.2015.5026

Overtreatment of low grade ductal carcinoma in situ

Translational Childhood Cancer Genomics: The Future Is Now

Abstract Full Text
JAMA Oncol. 2016;2(3):384-385. doi:10.1001/jamaoncol.2015.5076

This case series evaluates the use of integrative clinical sequencing and genetic counseling in the assessment and treatment of children and young adults with cancer.

Editorial

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials

Abstract Full Text
JAMA Oncol. 2016;2(3):300-301. doi:10.1001/jamaoncol.2015.4920

Timeliness in Breast Cancer Treatment—The Sooner, the Better

Abstract Full Text
JAMA Oncol. 2016;2(3):302-304. doi:10.1001/jamaoncol.2015.4506
Invited Commentary

Familial Carcinoma of Unknown Primary

Abstract Full Text
JAMA Oncol. 2016;2(3):346-347. doi:10.1001/jamaoncol.2015.4653

Pelvis Plus Prostate Radiation Therapy and the Risk of Death in Men With Newly Diagnosed Node-Positive Prostate Cancer

Abstract Full Text
JAMA Oncol. 2016;2(3):357-358. doi:10.1001/jamaoncol.2015.4342

Dose Escalation in Stage III Non–Small-Cell Lung Cancer: Patients Agree With the Clinical Results

Abstract Full Text
JAMA Oncol. 2016;2(3):368-369. doi:10.1001/jamaoncol.2015.4683
Editor's Note

Young Patients With Lung Cancer—An Understudied Population

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):321. doi:10.1001/jamaoncol.2015.4479

The Importance of Quality of Life Assessment

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):367-368. doi:10.1001/jamaoncol.2015.4087
Cancer Care Chronicles

Celebrate a Bad Day

Abstract Full Text
JAMA Oncol. 2016;2(3):299. doi:10.1001/jamaoncol.2015.5802
Comment & Response

Pathologic Abnormalities Behind Ductal Carcinoma In Situ Terminology

Abstract Full Text
JAMA Oncol. 2016;2(3):394-395. doi:10.1001/jamaoncol.2015.4843

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ—Reply

Abstract Full Text
JAMA Oncol. 2016;2(3):395-396. doi:10.1001/jamaoncol.2015.4840

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):395. doi:10.1001/jamaoncol.2015.4846

Treatment and Long-term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):396. doi:10.1001/jamaoncol.2015.4854

Effects of Standard Treatments for Ductal Carcinoma In Situ—Making Informed Choices

Abstract Full Text
JAMA Oncol. 2016;2(3):396-397. doi:10.1001/jamaoncol.2015.4857

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):397-398. doi:10.1001/jamaoncol.2015.4860

Treatment Recommendations for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):398. doi:10.1001/jamaoncol.2015.4863

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):398-399. doi:10.1001/jamaoncol.2015.4866

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):399. doi:10.1001/jamaoncol.2015.4872

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
JAMA Oncol. 2016;2(3):399-400. doi:10.1001/jamaoncol.2015.4875

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ—Reply

Abstract Full Text
JAMA Oncol. 2016;2(3):400-401. doi:10.1001/jamaoncol.2015.4878

Perspectives in Oncology Drug Pricing

Abstract Full Text
JAMA Oncol. 2016;2(3):401. doi:10.1001/jamaoncol.2015.5000

Perspectives in Oncology Drug Pricing

Abstract Full Text
JAMA Oncol. 2016;2(3):401-402. doi:10.1001/jamaoncol.2015.5003

Perspectives in Oncology Drug Pricing—Reply

Abstract Full Text
JAMA Oncol. 2016;2(3):402-403. doi:10.1001/jamaoncol.2015.4997

Perspectives in Oncology Drug Pricing

Abstract Full Text
JAMA Oncol. 2016;2(3):402. doi:10.1001/jamaoncol.2015.5006

340B Drug Pricing Program Reform

Abstract Full Text
JAMA Oncol. 2016;2(3):403. doi:10.1001/jamaoncol.2015.5400

340B Drug Pricing Program Reform—Reply

Abstract Full Text
JAMA Oncol. 2016;2(3):403-404. doi:10.1001/jamaoncol.2015.5403
Correction

Error in Author Affiliation Name

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):404. doi:10.1001/jamaoncol.2015.5756

Incomplete Conflict of Interest Disclosure

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):404. doi:10.1001/jamaoncol.2016.0048

Middle Initial Omitted From Author’s Name

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):404. doi:10.1001/jamaoncol.2016.0281
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):289. doi:10.1001/jamaoncol.2015.3492
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(3):287. doi:10.1001/jamaoncol.2015.3491
×